UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

Investigational new drugs, 2009-08, Vol.27 (4), p.379-386

2009

Volltextzugriff (PDF)

Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study

Gastroenterology (New York, N.Y. 1943), 1997-12, Vol.113 (6), p.1930-1937

1997

Volltextzugriff (PDF)

Gene-Based Vaccines and Immunotherapeutics

Proceedings of the National Academy of Sciences - PNAS, 2004-10, Vol.101 (Suppl 2), p.14567-14571

2004

Volltextzugriff (PDF)

A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma

Cancer gene therapy, 2003-04, Vol.10 (4), p.251-259

2003

Volltextzugriff (PDF)

Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients

Gene therapy, 2003-03, Vol.10 (5), p.386-395

2003

Volltextzugriff (PDF)

Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomas

Blood, 2004-09, Vol.104 (6), p.1631-1638

2004

Volltextzugriff (PDF)

494P - Phase I Safety and Tolerability of Once Daily Oral Afatinib (A) in Combination with Docetaxel (D) in Patients (PTS) with Relapsed or Refractory Advanced Solid Tumours

Annals of oncology, 2012-09, Vol.23, p.ix169-ix169

2012

Volltextzugriff (PDF)

Phase I Safety and Tolerability of Once Daily Oral Afatinib (A) (BIBW 2992) in Combination with Gemcitabine (G) in Patients (PTS) with Advanced Solid Tumours

Annals of oncology, 2012-09, Vol.23, p.ix165

2012

Volltextzugriff (PDF)

Phase I Safety and Tolerability of Once Daily Oral Afatinib (A) in Combination with Docetaxel (D) in Patients (PTS) with Relapsed or Refractory Advanced Solid Tumours

Annals of oncology, 2012-09, Vol.23, p.ix169

2012

Volltextzugriff (PDF)

478P - Phase I Safety and Tolerability of Once Daily Oral Afatinib (A) (BIBW 2992) in Combination with Gemcitabine (G) in Patients (PTS) with Advanced Solid Tumours

Annals of oncology, 2012-09, Vol.23, p.ix165-ix165

2012

Volltextzugriff (PDF)

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

The journal of gene medicine, 2003-08, Vol.5 (8), p.690-699

2003

Volltextzugriff (PDF)

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings

British Journal of Cancer, 2000-12, Vol.83 (11), p.1454-1461

2000

Volltextzugriff (PDF)

A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.8139-8139

2010

Volltextzugriff (PDF)

A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1–7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3015-3015

2009

Volltextzugriff (PDF)

Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3032-3032

2009

Volltextzugriff (PDF)

Vγ9Vδ2 T (γδ) lymphocytes: a promising approach for immunotherapy of solid tumors

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.3064-3064

2007

Volltextzugriff (PDF)

Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies: Part I: rationale

Neuromuscular disorders : NMD, 2002-10, Vol.12, p.S49-S51

2002

Volltextzugriff (PDF)

Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies: Part II: clinical protocol

Neuromuscular disorders : NMD, 2002-10, Vol.12, p.S45-S48

2002

Volltextzugriff (PDF)

Metastatic Breast Tumour Regression Following Treatment by a Gene‐Modified Vaccinia Virus Expressing MUC1 and IL‐2

BioMed research international, 2003, Vol.2003 (3), p.194-201

2003

Volltextzugriff (PDF)

Phase I/II study of adenovirus-interferon-γ (TG1042) in primary cutaneous lymphomas (CL)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3039-3039

2004

Volltextzugriff (PDF)

Phase I/II study of adenovirus-interferon-γ (TG1042) in primary cutaneous lymphomas (CL)

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3039-3039

2004

Volltextzugriff (PDF)

Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels

Cancer gene therapy, 2002-03, Vol.9 (3), p.289-295

2002

Volltextzugriff (PDF)

Vaccine immunotherapy with MVA-Muc1-IL2 (TG4010) in prostate cancer patients with biochemical failure

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4518-4518

2005

Volltextzugriff (PDF)

Phase II study of the cancer vaccine TG4010 in metastatic renal cell carcinoma

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.4653-4653

2005

Volltextzugriff (PDF)

MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC) : Interim phase II data

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.2544-2544

2004

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(56)
Bücher
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(30)
Life Sciences & Biomedicine
(29)
Humans
(22)
Male
(18)
Biological And Medical Sciences
(13)
Female
(12)
Medical Sciences
(10)
Middle Aged
(10)
Adult
(9)
Aged
(9)
Animals
(9)
Cytokines
(8)
Life Sciences
(8)
Oncology
(8)
Immunotherapy
(7)
Mice
(7)
Biotechnology & Applied Microbiology
(6)
Genetic Therapy - Methods
(6)
Immunotherapy - Methods
(6)
Medicine, Research & Experimental
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study

Gene-Based Vaccines and Immunotherapeutics

A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma

Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients

Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomas

494P - Phase I Safety and Tolerability of Once Daily Oral Afatinib (A) in Combination with Docetaxel (D) in Patients (PTS) with Relapsed or Refractory Advanced Solid Tumours

Phase I Safety and Tolerability of Once Daily Oral Afatinib (A) (BIBW 2992) in Combination with Gemcitabine (G) in Patients (PTS) with Advanced Solid Tumours

Phase I Safety and Tolerability of Once Daily Oral Afatinib (A) in Combination with Docetaxel (D) in Patients (PTS) with Relapsed or Refractory Advanced Solid Tumours

478P - Phase I Safety and Tolerability of Once Daily Oral Afatinib (A) (BIBW 2992) in Combination with Gemcitabine (G) in Patients (PTS) with Advanced Solid Tumours

Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings

A phase I study of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma

A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1–7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML)

Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results

Vγ9Vδ2 T (γδ) lymphocytes: a promising approach for immunotherapy of solid tumors

Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies: Part I: rationale

Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies: Part II: clinical protocol

Metastatic Breast Tumour Regression Following Treatment by a Gene‐Modified Vaccinia Virus Expressing MUC1 and IL‐2

Phase I/II study of adenovirus-interferon-γ (TG1042) in primary cutaneous lymphomas (CL)

Phase I/II study of adenovirus-interferon-γ (TG1042) in primary cutaneous lymphomas (CL)

Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels

Vaccine immunotherapy with MVA-Muc1-IL2 (TG4010) in prostate cancer patients with biochemical failure

Phase II study of the cancer vaccine TG4010 in metastatic renal cell carcinoma

MVA-MUC1-IL2 vaccine immunotherapy for advanced non small cell lung cancer (NSCLC) : Interim phase II data

Suchergebnisse filtern